#AQST Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

#AQST Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
🚨 JUST IN: $AQST
Aquestive resubmits Anaphylm NDA to FDA; addresses CRL with positive human factor/PK data
#SEC #stocks #investing #AQST #Regulatory
🔗 secwatch.observer
#AQST Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film